LianBio, which is developing in-licensed therapies for a variety of indications in China, raised $325 million by offering 20.3 million ADSs at $16, within the range of $15 to $17.
LianBio is focused on the in-licensing, development, and commercialization of therapeutics in Greater China, including Mainland China, Hong Kong, Taiwan, Macau, and other Asian markets. The company currently has nine programs across five therapeutic areas, including oncology, cardiovascular, and inflammatory diseases. With dual headquarters in China and the United States, LianBio has in-licensed programs from Bristol Myers Squibb, BridgeBio, and Pfizer, in which LianBio typically buys the rights to pursue the program within China, in exchange for royalties.
LianBio plans to list on the Nasdaq under the symbol LIAN. Goldman Sachs, Jefferies, and BofA Securities acted as joint bookrunners on the deal.
